the journal of cardiovascular surgery-360期刊网

您当前的位置: 首页 > SCI文献 > The Journal of cardiovascular surgery

The Journal of cardiovascular surgery 在可比患者队列中比较血管内动脉瘤封闭和修复与造影剂使用和放射的关系。

影响因子：1.595 DOI：10.23736/S0021-9509.18.10206-0

作者： Peters AS,Hatzl J,Bischoff MS,Böckler D 发表时间：2020-07-09 12:20:34

from：《JOURNAL OF CARDIOVASCULAR SURGERY》

keywords： Peters ASHatzl JBischoff MSBöckler D

关键词：

Abstract

BACKGROUND:Due to recent advances in endograft design and percutaneous access, technical success could be increased during endovascular aneurysm repair (EVAR). Beside EVAR, endovascular aneurysm sealing (EVAS) provides an alternative procedure to treat aneurysms. To compare the two methods, additional benchmark criteria should be evaluated: Screening time, dose area product (DAP), procedure time and contrast use. In this study these technical variables are analyzed for EVAS vs. EVAR in comparable patient cohorts. METHODS:It is a retrospective, single-center study. Only elective cases of infrarenal aortic aneurysms were included, all treated by the same surgeon (D.B.). Procedures were performed within the instructions for use without additional procedures. All operations were undertaken in a hybrid operating theatre. For EVAR, only the Medtronic Endurant® and the Gore C3 Excluder® were included. For EVAS the Nellix® from Endologix was used. RESULTS:Between 2012 and 2016, 67 patients were treated with EVAS and 40 with EVAR; of these 20 and 16 could be introduced into the study respectively. Median age was 73 and 72 years respectively (only men). The two groups were comparable in terms of BMI, GFR and ASA-status. Screening time was reduced for EVAS (10.6 vs. 14.5 min., P<0.01), while the DAP was not significantly different. Procedural time and contrast use were increased for EVAS (120 vs. 96 min., 120 vs. 79 mL, P<0.01). CONCLUSIONS:Especially the younger EVAS-procedure requires ongoing review in order to further reduce contrast agent. Reduced screening time for EVAS does not have a significant impact on radiation dose.

摘要

背景: 由于近期内移植设计和经皮入路的进展，动脉瘤腔内修复术 (EVAR) 的技术成功可能会增加。除EVAR外，血管内动脉瘤封闭术 (EVAS) 提供了治疗动脉瘤的替代方法。为了比较两种方法，应评估额外的基准标准: 筛选时间、剂量面积产物 (DAP) 、手术时间和造影剂使用。在本研究中，在可比患者队列中分析EVAS与EVAR的这些技术变量。方法: 这是一项回顾性、单中心研究。仅纳入肾下主动脉瘤的择期病例，均由同一外科医生 (D.B.) 治疗。在使用说明内执行程序，无需额外程序。所有手术均在混合手术室进行。对于EVAR来说，只有美敦力的Endurant®和戈尔C3 排斥者®包括在内。对于EVAS的Nellix®使用了Endologix。结果: 在 2012 和 2016 之间，67 例患者接受EVAS治疗，40 例患者接受EVAR治疗; 其中 20 例和 16 例分别可以引入研究。中位年龄分别为 73 岁和 72 岁 (仅男性)。两组在BMI、GFR和ASA状态方面具有可比性。EVAS的筛选时间缩短 (10.6 vs. 14.5 min，P<0.01)，而DAP无显著差异。EVAS的手术时间和造影剂使用增加 (120 vs. 96 min.，120 vs. 79 mL，P<0.01)。结论: 尤其是年轻的EVAS手术需要持续审查，以进一步减少造影剂。EVAS筛查时间的减少对辐射剂量没有显著影响。

期刊介绍

《JOURNAL OF CARDIOVASCULAR SURGERY》 (点击进入期刊详情)

英文简介 : A Journal on the Diagnosis and Therapy of Cardiac Thoracic and Vascular Diseases. Frequency: Bi-Monthly. Affiliated with the Society of Cardio-Thoracic Surgeons.

中文简介 : （来自Google、百度翻译）心胸血管疾病的诊断和治疗杂志。频率：双月。隶属于心胸外科医师协会。

CIRCULATION RESEARCH 期刊中科院评价数据

新中科院分区

大类(学科)	小类(学科)	学科排名
医学	CARDIAC & CARDIOVASCULAR SYSTEMS (心脏和心血管系统) PERIPHERAL VASCULAR DISEASE (外周血管病) SURGERY (外科)	110/128 59/65 145/200

大类(学科)

小类(学科)

学科排名

医学

CARDIAC & CARDIOVASCULAR SYSTEMS (心脏和心血管系统)

PERIPHERAL VASCULAR DISEASE (外周血管病)

SURGERY (外科)

110/128
59/65
145/200

新发布的期刊年发文量